The DOI matches its Crossref record; 131 of the 132 references it cites were found in a registry or an index.
Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
Open accessAbstract
The cancer stem cell (SC) theory proposes that a population of SCs serves as the driving force behind fundamental tumor processes, including metastasis, recurrence, and resistance to therapy. The standard of care for patients with stage III and high-risk stage II colorectal cancer (CRC) includes surgery and adjuvant chemotherapy. Fluoropyrimidines and their combination with oxaliplatin increased the cure rates, being able to eradicate the occult metastatic SC in a fraction of patients. The treatment for unresectable metastatic CRC is based on chemotherapy, antibodies to VEGF and EGFR, and tyrosine-kinase inhibitors. Immunotherapy is used in MSI-H tumors. Currently used drugs target dividing cells and, while often effective at debulking tumor mass, these agents have largely failed to cure metastatic disease. SCs are generated either due to genetic and epigenetic alterations in stem/progenitor cells or to the dedifferentiation of somatic cells where diverse signaling pathways such as Wnt/β-catenin, Hedgehog, Notch, TGF-β/SMAD, PI3K/Akt/mTOR, NF-κB, JAK/STAT, DNA damage response, and Hippo-YAP play a key role. Anti-neoplastic treatments could be improved by elimination of SCs, becoming an attractive target for the design of novel agents. Here, we present a review of clinical trials assessing the efficacy of targeted treatment focusing on these pathways in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, colorectal CSCs exhibit significant cellular plasticity in that they can transition between stem like and differentiated states, which further increases tumor heterogeneity and escape from therapeutic targeting [72].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007) · Nature · doi:10.1038/nature05372 · Cited by 4,087
Identification and expansion of human colon-cancer-initiating cells
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007) · Nature · doi:10.1038/nature05384 · Cited by 3,998
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 1×
“Regorafenib is a multitargeted kinase inhibitor approved for the treatment of patients with metastatic CRC (mCRC) who are refractory to standard chemotherapy [18].”
BackgroundCrypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166
Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study
Yu, H., Lin, L., Zhang, Z., Zhang, H., & Hu, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00312-6 · Cited by 2,135
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“A second key approach for targeting colorectal CSCs involves the suppression of specific signaling pathways that are critical for CSC maintenance and proliferation [69,71,72].”
InfluentialMengistu, B. A., Tsegaw, T., Demessie, Y., Getnet, K., Bitew, A. B., Kinde, M. Z., Berihun, A. M., Mebratu, A. S., Mekasha, Y. T., Feleke, M. G., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03558-0 · Cited by 85
Chen, Q., Shen, M., Yan, M., Han, X., Mu, S., Li, Y., Luo, L., Wang, Y., Li, S., Li, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05518-8 · Cited by 39
Cancer stem cells in focus: Deciphering the dynamic functional landscape of stemness in cancer
Nwokolo, G. C., Ganesan, T. S., Pors, K., Falconer, R. A., & Sneha, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189440 · Cited by 14
GNG2 inhibits brain metastases from colorectal cancer via PI3K/AKT/mTOR signaling pathway
Luo, C., Xiao, Z., & Yang, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-85592-0 · Cited by 10
Metadata
- Authors
- Martínez-Pérez, J., Torrado, C., Domínguez-Cejudo, M. A., & Valladares-Ayerbes, M.
- Affiliations
- Medical Oncology Department, Hospital Universitario Virgen del Rocio (HUVR), Avenida de Manuel Siurot s/n, 41013 Seville, Spain
- The University of Texas MD Anderson Cancer Center (US)
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario Virgen del Rocio (HUVR), Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Avenida de Manuel Siurot s/n, 41013 Seville, Spain
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-06-05
- Volume
- 25
- Issue
- 11
- Pages
- 6220
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11172446
- OpenAlex
- W4399366851
- Cited by
- 18
- References
- 132
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Keywords
- colorectal cancer, cancer stem cells, targeted therapy, metastatic colorectal cancer, adjuvant chemotherapy, fluoropyrimidine, oxaliplatin, VEGF inhibitors, EGFR inhibitors, tyrosine kinase inhibitors, immunotherapy, microsatellite instability-high, Wnt/β-catenin signaling, Hedgehog signaling, Notch signaling, TGF-β/Smad signaling, PI3K/AKT/mTOR pathway, NF-κB signaling, JAK/STAT signaling, DNA damage response, Hippo/YAP signaling, dedifferentiation, clinical trials
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplastic Stem Cells, Colorectal Neoplasms, Signal Transduction, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted Treatment against Cancer Stem Cells in Colorectal Cancer. https://app.cochat.ai/papers/10.3390/ijms25116220
- The paper
- Martínez-Pérez, J., Torrado, C., Domínguez-Cejudo, M. A., & Valladares-Ayerbes, M. (2024). Targeted Treatment against Cancer Stem Cells in Colorectal Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25116220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
